Dr. Senthil Damodaran, MD, PhD
Claim this profileMD Anderson Cancer Center
Studies Breast Cancer
Studies Solid Tumors
5 reported clinical trials
9 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
Stage III
2Solid Tumors
Affiliated Hospitals
Clinical Trials Senthil Damodaran, MD, PhD is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
DB-1305
for Solid Tumors
This trial is testing a new drug called DB-1305 to see if it is safe for patients with advanced solid tumors that are hard to treat. The study will begin with smaller amounts of the drug and increase them over time to find the safest and most effective dose.
Recruiting1 award Phase 1 & 24 criteria
More about Senthil Damodaran, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Senthil Damodaran, MD, PhD has experience with
- Fulvestrant
- Trastuzumab Deruxtecan
- Valemetostat
- DB-1305
- Talazoparib
- Futibatinib
Breakdown of trials Senthil Damodaran, MD, PhD has run
Breast Cancer
Solid Tumors
Fibroblast Growth Factor Receptor 1 High Amplification
No disease or condition mentioned.
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Senthil Damodaran, MD, PhD specialize in?
Senthil Damodaran, MD, PhD focuses on Breast Cancer and Solid Tumors. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Senthil Damodaran, MD, PhD currently recruiting for clinical trials?
Yes, Senthil Damodaran, MD, PhD is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Senthil Damodaran, MD, PhD has studied deeply?
Yes, Senthil Damodaran, MD, PhD has studied treatments such as Fulvestrant, Trastuzumab deruxtecan, Valemetostat.
What is the best way to schedule an appointment with Senthil Damodaran, MD, PhD?
Apply for one of the trials that Senthil Damodaran, MD, PhD is conducting.
What is the office address of Senthil Damodaran, MD, PhD?
The office of Senthil Damodaran, MD, PhD is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.